A new long-acting reversible contraception (LARC) method offering protection from unplanned pregnancy for up to five years has been launched by Bayer. Kyleena releases a low daily dose of levonorgestrel in a five-year intrauterine system, using a small T-body and narrow insertion tube.

Lars Bruening, Bayer’s CEO and UK head of pharma, says: “Kyleena provides women with an additional, reliable and reversible contraceptive option.”